Market Research Report - 288794
Europe Markets for Orthopedic Biomaterials 2011-2021
|Published by||iData Research Inc.|
|Published||Content info||350 Pages|
|Europe Markets for Orthopedic Biomaterials 2011-2021|
|Published: June 1, 2015||Content info: 350 Pages||
The European market for orthopedic materials is segmented into bone graft substitutes (BGS), which includes allograft, synthetic and demineralized bone matrices (DBM); bone morphogenetic protein (BMP) growth factors; hyaluronic acid (HA) viscosupplementation; and autologous chondrocyte implantation (ACI).
The European orthopedic biomaterials market includes bone graft substitutes (BGS), hyaluronic acid (HA) viscosupplementation injections, bone morphogenetic protein (BMP) growth factor therapy and autologous chondrocyte implantations (ACI). The HA market experienced significant contractions in 2012 and 2013 due to the extreme price competition resulting from an increase in competition, especially in Germany.